MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Nephropathy

  • Home
  • Nephropathy
Glucagon-Like Peptide-1 Receptor Agonists and Vascular Protection: Mitigating Systemic and Ocular Risks in High-Risk Type 2 Diabetes
Posted inClinical Updates Diabetes & Endocrinology news Ophthalmology

Glucagon-Like Peptide-1 Receptor Agonists and Vascular Protection: Mitigating Systemic and Ocular Risks in High-Risk Type 2 Diabetes

Posted by By MedXY 04/27/2026
A large-scale cohort study demonstrates that GLP-1 RAs significantly reduce macrovascular and microvascular complications, including proliferative retinopathy and retinal vein occlusion, in patients with pre-existing diabetic retinopathy.
Read More
Beyond HbA1c: How Diabetes Subtyping Predicts Comorbidities and Mortality Over 14 Years
Posted inCardiology Diabetes & Endocrinology news

Beyond HbA1c: How Diabetes Subtyping Predicts Comorbidities and Mortality Over 14 Years

Posted by By MedXY 01/07/2026
A landmark Swedish cohort study demonstrates that diabetes subgroups, particularly those characterized by insulin resistance and deficiency, carry significantly higher risks for end-organ damage and cardiovascular mortality than previously identified by standard glycemic markers.
Read More
  • Intravitreal Bevacizumab versus Laser Therapy in Retinopathy of Prematurity: Analyzing Retreatment Rates, Timing, and Risk Predictors
  • Unraveling the Complex 3D Architecture of Outer Retinal Tubulation in Bietti Crystalline Dystrophy
  • Idiopathic Subglottic Stenosis in Pregnancy: Safety, Clinical Course, and Management Insights from a Case-Control Study
  • Rare But Risky: Clinical Implications of Pneumothorax Following Thyroidectomy and Parathyroidectomy
  • Navigating the Shift: Insights into a Department’s Transition from Total to Intracapsular Tonsillectomy
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top